Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Grifols Sa (OTC: GIKLY).

Full DD Report for GIKLY

You must become a subscriber to view this report.


Recent News from (OTC: GIKLY)

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
- Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the "Clinical Trials on Alzheimer's Disease" (CTAD) congress on October 27, 2018 in Barcelona . - AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plas...
Source: PR Newswire
Date: October, 27 2018 03:30
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
BARCELONA, Spain , Oct. 12, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, received approval  from the U.S. Food & Drug Administration ...
Source: PR Newswire
Date: October, 12 2018 09:50
Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support
BARCELONA, Spain , Oct. 8, 2018 /PRNewswire/ -- The importance of plasma is recognized during International Plasma Awareness Week, October 8-12 . Grifols continues its commitment to plasma-derived medical treatments. These recent developments include: FEBRUARY 2018 : A higher p...
Source: PR Newswire
Date: October, 08 2018 14:57
Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio
BOWLING GREEN, Ohio , Sept. 24, 2018 /PRNewswire/ -- Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio . The 13,000 square foot state-of-the-art facility official...
Source: PR Newswire
Date: September, 24 2018 12:59
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
EMERYVILLE, Calif. , Aug. 16, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, recentl...
Source: PR Newswire
Date: August, 16 2018 08:00
Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System
BARCELONA, Spain , Aug. 14, 2018 /PRNewswire/ --   Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that the U.S. Food and Drug Administration (...
Source: PR Newswire
Date: August, 14 2018 08:00
Grifols Expands its NAT Solutions Portfolio with New FDA Approvals for Two Assays
BARCELONA, Spain , June 19, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that it has received approval from the U.S. Food...
Source: PR Newswire
Date: June, 19 2018 08:25
Grifols (GIKLY) Investor Presentation - Slideshow
The following slide deck was published by Grifols Sa ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 08 2018 14:35
Grifols Launches a New Testing Service for Patients Treated with Daratumumab
BARCELONA, Spain , May 31, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization testing service to its...
Source: PR Newswire
Date: May, 31 2018 09:00
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
BARCELONA, Spain , May 14, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced the expansion of its blood typing solutions portf...
Source: PR Newswire
Date: May, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-18N/A13.14N/AN/A33
2018-12-1713.1813.1413.1813.14237
2018-12-1413.2013.2013.2013.203,186
2018-12-13N/A13.90N/AN/A46
2018-12-12N/A13.90N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14993,1863.1073Cover
2018-11-30183183100.0000Short
2018-11-274985,5039.0496Cover
2018-11-269255816.4875Cover
2018-11-196136,4769.4657Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GIKLY.


About Grifols Sa (OTC: GIKLY)

Logo for Grifols Sa (OTC: GIKLY)

Not available

 

Contact Information

 

 

Current Management

  • Victor Grifols Roura / CEO
  • Victor Grifols Roura / Chairman

Current Share Structure

  • Authorized: 12,885,099,562 - 03/12/2018

 


Recent Filings from (OTC: GIKLY)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 20 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: April, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 28 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 26 2018

 

 


Daily Technical Chart for (OTC: GIKLY)

Daily Technical Chart for (OTC: GIKLY)


Stay tuned for daily updates and more on (OTC: GIKLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GIKLY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GIKLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GIKLY and does not buy, sell, or trade any shares of GIKLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/